News

RedHill Biopharma Ltd. a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration has granted orphan-drug designation to opaganib for treatment of neuroblastoma, a type of childhood cancer that develops from immature nerve cells and accounts for 15% of all pediatric cancer-related deaths.

Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China’s National Medical Products Administration has approved Dupert®（fulzerasib, GFH925/IBI351）for the treatment of patients

Boehringer Ingelheim India is pleased to announce a strategic distribution partnership with Vvaan Lifesciences Private Limited for their Pet Parasiticide portfolio. This collaboration, a key initiative under our India Animal Health Accelerated Growth Plan (AGP),

Amgen today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the treatment of moderate to severe plaque psoriasis in children and adolescents

RedHill Biopharma Ltd. a specialty biopharmaceutical company, today announced the launch of Talicia (omeprazole magnesium, amoxicillin and rifabutin)[4] in the United Arab Emirates

Nnovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases,

Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung

BerGenBio ASA a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today a collaboration with Tempus, a technology company leading the adoption of AI to advance precision

Glenmark Therapeutics Inc., USA is pleased to announce it has launched1 Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC); compare to the active ingredient in Pataday®2 Twice Daily Relief.